His main research concerns Internal medicine, Endocrinology, Pharmacology, Pharmacokinetics and Cell biology. He works mostly in the field of Internal medicine, limiting it down to topics relating to Cardiology and, in certain cases, Confidence interval and Mean arterial pressure. His Endocrinology study frequently links to other fields, such as Odanacatib.
His Pharmacology research includes elements of Biomarker and Antibacterial agent. His study in the fields of Cmax under the domain of Pharmacokinetics overlaps with other disciplines such as Raltegravir Potassium, Raltegravir and Integrase inhibitor. The concepts of his Cell biology study are interwoven with issues in Neurite, Immunology and Fibroblast growth factor.
His primary areas of investigation include Pharmacology, Internal medicine, Pharmacokinetics, Endocrinology and Crossover study. His work in the fields of Pharmacology, such as Tolerability and Pharmacodynamics, intersects with other areas such as Raltegravir. Anacetrapib is the focus of his Internal medicine research.
He studied Pharmacokinetics and Sitagliptin that intersect with Dipeptidyl peptidase-4 inhibitor and Dipeptidyl peptidase-4. His study explores the link between Endocrinology and topics such as Cell biology that cross with problems in Nerve growth factor and Biochemistry. He has included themes like Anesthesia and Randomized controlled trial in his Crossover study study.
His primary areas of study are Pharmacology, Internal medicine, Pharmacokinetics, Endocrinology and Anacetrapib. His work in the fields of Tolerability overlaps with other areas such as Midazolam. His Gastroenterology research extends to the thematically linked field of Internal medicine.
His studies in Pharmacokinetics integrate themes in fields like Dyslipidemia, Adverse effect and Dosing. His work in Endocrinology tackles topics such as Antigen presentation which are related to areas like Molecular biology. His research in Anacetrapib tackles topics such as Atorvastatin which are related to areas like Apolipoprotein B, Metabolism and Statin.
John A. Wagner mainly focuses on Internal medicine, Pharmacology, Pharmacokinetics, Endocrinology and Atorvastatin. John A. Wagner performs multidisciplinary study in the fields of Internal medicine and Generalized estimating equation via his papers. The study incorporates disciplines such as Boceprevir, Personalized medicine, Hepatitis C and Hepatitis C virus in addition to Pharmacology.
His Pharmacokinetics research incorporates elements of Gastroenterology and Needle biopsy. He integrates Endocrinology and In patient in his research. His study looks at the intersection of Atorvastatin and topics like Anacetrapib with Apolipoprotein B, Triglyceride and Total population.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Identification of a cyclic-AMP-responsive element within the rat somatostatin gene.
Marc R. Montminy;Kevin A. Sevarino;John A. Wagner;Gail Mandel.
Proceedings of the National Academy of Sciences of the United States of America (1986)
Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity
Utpal B. Pajvani;Meredith Hawkins;Terry P. Combs;Michael W. Rajala.
Journal of Biological Chemistry (2004)
Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization
Terry P. Combs;John A. Wagner;Joel Berger;Tom Doebber.
Fit-for-purpose method development and validation for successful biomarker measurement.
Jean W. Lee;Viswanath Devanarayan;Yu Chen Barrett;Russell Weiner.
Pharmaceutical Research (2006)
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes
Gary A. Herman;Arthur Bergman;Catherine Stevens;Paul Kotey.
The Journal of Clinical Endocrinology and Metabolism (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Gary A. Herman;Cathy Stevens;Kristien Van Dyck;Arthur Bergman.
Clinical Pharmacology & Therapeutics (2005)
Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia.
Mitsutoshi Endoh;Kenneth Maiese;John Wagner.
Brain Research (1994)
RETINOIDS REGULATE STEM CELL DIFFERENTIATION
Lorraine J. Gudas;John A. Wagner.
Journal of Cellular Physiology (2011)
Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop
Abhijit Guha;Kathleen Dashner;Peter L. Mc Black;John A. Wagner.
International Journal of Cancer (1995)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna;Matt S Anderson;Arthur J Bergman;Bo Jin.
The Lancet (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: